Ketorolac/phenylephrine - Omeros Corporation

Drug Profile

Ketorolac/phenylephrine - Omeros Corporation

Alternative Names: Omidria; OMS-302; OMS-302-PE; Phenylephrine and ketorolac injection 1%/0.3%; Phenylephrine/ketorolac

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Omeros Corporation
  • Class Analgesics; Anti-inflammatories; Antihypotensives; Decongestants; Ethanolamines; Eye disorder therapies; Indoles; Mydriatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Urologics
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Miosis; Postoperative pain

Most Recent Events

  • 12 Dec 2017 Registered for Miosis (In adolescents, In children, In infants, In neonates, Prevention) in USA (Intraocular)
  • 12 Dec 2017 Registered for Postoperative pain (In adolescents, In children, In infants, In neonates) in USA (Intraocular)
  • 12 Dec 2017 The US FDA approved sNDA under Priority Review for Postoperative pain (In adolescents, In children, In infants, In neonates) and Miosis (In adolescents, In children, In infants, In neonates, Prevention) in USA (Intraocular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top